As Novartis turns the calendar on a new year, the Swiss drugmaker is elaborating further on plans for the $23 billion U.S.

Five months ago, J&J also revealed its plan to spend $2 billion over the next 10 years to operate a 160,000-square-foot ...

Early launch numbers of Brinsupri are so strong that Insmed couldn’t wait for the J.P. Morgan Healthcare Conference to share ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

In the past three weeks, a flurry of licensing deals with Chinese biotechs were announced featuring AbbVie, AstraZeneca, ...

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the ...

As AstraZeneca floods money into the U.S. market with a wide-ranging investment plan, the company has tapped an in-house ...

Less than two weeks ago, Vanda scored an FDA approval for motion sickness pill, Nereus. The decision came 15 months after the ...

After a turbulent 2025, the biopharma industry is heading into the new year with major questions still unresolved. | In this ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

Chief among the factors driving a sense of optimism among the biopharma leaders was the unfreezing of the biotech investing ...

Viking has identified Neil Aubuchon as the person to oversee its commercial preparations. Aubuchon has joined the biotech as ...